29 Metaplastic breast carcinoma (MBC) is a clinically aggressive and rare subtype of breast cancer, 30 with similar features to basal-like breast cancers. Due rapid growth rates and characteristic 31 heterogeneity, MBC is often unresponsive to standard chemotherapies; and novel targeted 32 therapeutic discovery is urgently needed. Histone deacetylase inhibitors (DACi) suppress tumor 33 growth and metastasis through regulation of the epithelial-to-mesenchymal transition axis in 34 various cancers, including basal-like breast cancers. 35 We utilized a new MBC patient-derived xenograft (PDX) to examine the effect of DACi therapy 36 on MBC. Cell morphology, cell cycle-associated gene expressions, transwell migration, and 37 metastasis were evaluated in patient-derived cells and tumors after treatment with romidepsin 38 and panobinostat. Derivations of our PDX model, including cells, spheres, organoids, explants, 39 and in vivo implanted tumors were treated. Finally, we tested the effects of combining DACi 40 with approved chemotherapeutics on relative cell biomass.
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The associations amongst EMT, metastasis, and chemotherapeutic resistance are not 147 completely understood. Expression of EMT-associated genes was initially thought to drive 148 epithelial stem cell properties and breast cancer metastasis [41] [42] [43] . Other hypotheses suggest 149 that EMT is not required for metastasis [44] and that epithelial-and mesenchymal-like states are 150 mediated by the tumor microenvironment [45] . Despite this lack of congruency, targeted 151 therapies that reverse the mesenchymal phenotype of cancer cells have been shown to improve 152 the sensitivity of tumors to cytotoxic effects of chemotherapeutic agents [44, 46, 47] 365 sectioned at 4 µM, and mounted on glass slides. Mounted sections were then exposed to xylene, 366 ethanol, and acetic acid with intermittent washings with water before being stained with 367 hematoxylin and eosin. After staining, slides were then again exposed to ethanol and xylene to 368 complete the protocol. 487 WNT3, and ZEB2 in addition to other mesenchymal genes ( Fig 4A, S2 Fig) . In cell cycle 488 signaling pathways, romidepsin increased CDNK1A expression and downregulated HDAC7, 489 PLK1, AURKB, PLK4, CENPA, AURKA, MKI67, and FOXM1 ( Fig 4B) . Romidepsin also 490 affected ECM-related genes including upregulation of MMP9 and downregulation of HAS2, 491 PLAU, ADAMTS1, ECM2, ADAMTS5, DDR2, ADAM9, MMP14, and SERPINB1 (Fig 4C) .
